Castle Biosciences, Inc.

US$32.52As of Sun 8 Nov 2026, 12:00 UTC
NASDAQ:CSTLHealthcare
Country USA
PE (Fwd) •••
TSR 7Y CAGR 7.17%
Div yield —
ROE (4.87%)
Diagnostics & Research
Beta (5Y) 0.95
PE TTM —
TSR TTM 27.53%
Mkt cap US$1.002B
ROIC (11.75%)
SE Grade™
Value
Quality
Moat
Consensus
Reference
$38
17.36%
20.28%
Hold 2|11|5|1|10
4Q25
1Q26
2Q26
3Q26
Earnings per share$
0.57
0.59
0.63
0.68
6.36%
2.89%
2.28%
13.73%
Revenue$M
91.90
96.45
98.01
101.0
11.92%
11.04%
9.66%
13.32%
Peers (US$1.002B)
Cap (US$)
PE
1.285B
—
1.094B
—
925.3M
17.91x
Capital
TTM
5Y
10Y
Leveragex
0.103
0.530
0.498
EBIT/Intx
0.451
0.993
0.968
Own earn%
7.82
296.72
242.72
Sh yield%
10.89
17.54
17.77
Owners
Insiders/Inst%
1.17
38.47
Short interest%
2.56
SBC / revenue%
5.59
Record
10Y
Profitable years
10/10
Revenue growth years
10/10
EPS growth years
10/10
Dividend streakyrs
17
Op margin range%
0–6
$1 testx
−0.7
Incr. ROIC%
16